Moreover, in previous studies, IFNγ has the potential to be used clinically in the treatment of malignant glioma [53], ovarian cancer [54], and as a promising adjunct to be used to other immunotherapeutic modalities. This evidence concerns the gene IFNG and ovarian carcinoma.